Establishment and validation of a multigene model to predict the risk of relapse in hormone receptor-positive early-stage Chinese breast cancer patients  

作　　者：Jiaxiang Liu Shuangtao Zhao Chenxuan Yang Li Ma Qixi Wu Xiangzhi Meng Bo Zheng Changyuan Guo Kexin Feng Qingyao Shang Jiaqi Liu Jie Wang Jingbo Zhang Guangyu Shan Bing Xu Yueping Liu Jianming Ying Xin Wang Xiang Wang 

机构地区：[1]Department of Breast Surgical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]Department of Thoracic Surgery,Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital,Capital Medical University,Beijing 101149,China [3]Breast Center,The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei 050035,China [4]Research and Development Department,Beijing USCI Medical Laboratory,Beijing 100195,China [5]Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [6]Department of Ultrasound,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [7]Department of Pathology,The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei 050011,China

出　　处：《Chinese Medical Journal》2023年第2期184-193,共10页中华医学杂志（英文版）

基　　金：supported by the National Key Research and Development Program of China(2019YFE0110000);National Natural Science Foundation of China(82072097);CAMS Innovation Fund for Medical Science(CIFMS)(2020-I2M-C&T-B-069,2021-I2M-1-014);and Beijing Hope Run Special Fund of Cancer Foundation of China(LC2020A18).

摘　　要：Background: Breast cancer patients who are positive for hormone receptor typically exhibit a favorable prognosis. It is controversial whether chemotherapy is necessary for them after surgery. Our study aimed to establish a multigene model to predict the relapse of hormone receptor-positive early-stage Chinese breast cancer after surgery and direct individualized application of chemotherapy in breast cancer patients after surgery. Methods: In this study, differentially expressed genes (DEGs) were identified between relapse and nonrelapse breast cancer groups based on RNA sequencing. Gene set enrichment analysis (GSEA) was performed to identify potential relapse-relevant pathways. CIBERSORT and Microenvironment Cell Populations-counter algorithms were used to analyze immune infiltration. The least absolute shrinkage and selection operator (LASSO) regression, log-rank tests, and multiple Cox regression were performed to identify prognostic signatures. A predictive model was developed and validated based on Kaplan-Meier analysis, receiver operating characteristic curve (ROC). Results: A total of 234 out of 487 patients were enrolled in this study, and 1588 DEGs were identified between the relapse and nonrelapse groups. GSEA results showed that immune-related pathways were enriched in the nonrelapse group, whereas cell cycle- and metabolism-relevant pathways were enriched in the relapse group. A predictive model was developed using three genes ( CKMT1B , SMR3B , and OR11M1P ) generated from the LASSO regression. The model stratified breast cancer patients into high- and low-risk subgroups with significantly different prognostic statuses, and our model was independent of other clinical factors. Time-dependent ROC showed high predictive performance of the model. Conclusions: A multigene model was established from RNA-sequencing data to direct risk classification and predict relapse of hormone receptor-positive breast cancer in Chinese patients. Utilization of the model could provide individualized evaluation of chemothe

关 键 词：Breast neoplasms CKMT1B OR11M1P Predictive model Prognosis Risk score SMR3B 

分 类 号：R737.9[医药卫生—肿瘤]